Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Julphar
Colorcon
AstraZeneca
Accenture
Mallinckrodt
Chinese Patent Office
Fuji
Argus Health

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021226

« Back to Dashboard

NDA 021226 describes KALETRA, which is a drug marketed by Abbvie and is included in three NDAs. It is available from nine suppliers. There are sixteen patents protecting this drug and two Paragraph IV challenges. Additional details are available on the KALETRA profile page.

The generic ingredient in KALETRA is lopinavir; ritonavir. There are thirteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the lopinavir; ritonavir profile page.
Summary for 021226
Tradename:KALETRA
Applicant:Abbvie
Ingredient:lopinavir; ritonavir
Patents:5
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength133.3MG;33.3MG
Approval Date:Sep 15, 2000TE:RLD:No
Patent:➤ Sign UpPatent Expiration:May 7, 2018Product Flag?Substance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:May 7, 2018Product Flag?Substance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:May 7, 2018Product Flag?Substance Flag?Delist Request?

Expired US Patents for NDA 021226

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie KALETRA lopinavir; ritonavir CAPSULE;ORAL 021226-001 Sep 15, 2000 ➤ Sign Up ➤ Sign Up
Abbvie KALETRA lopinavir; ritonavir CAPSULE;ORAL 021226-001 Sep 15, 2000 ➤ Sign Up ➤ Sign Up
Abbvie KALETRA lopinavir; ritonavir CAPSULE;ORAL 021226-001 Sep 15, 2000 ➤ Sign Up ➤ Sign Up
Abbvie KALETRA lopinavir; ritonavir CAPSULE;ORAL 021226-001 Sep 15, 2000 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Medtronic
McKinsey
Boehringer Ingelheim
Fuji
Deloitte
Dow
Accenture
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.